Topical Antibiotics in Dermatology: Emerging Patterns of Resistance

Dermatologic Clinics

Volumn 27, Issue 1, 2009, Pages 25-31

  Elston, Dirk M ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Acne; Bacterial; Infection; Resistance; Skin

Indexed keywords

ACTICOAT; ANTIBIOTIC AGENT; BACITRACIN; BACITRACIN PLUS NEOMYCIN PLUS POLYMYXIN B; BACTIGRASS; BENZALKONIUM CHLORIDE; BENZOYL PEROXIDE; BURSERA SIMARUBA EXTRACT; CHLORHEXIDINE GLUCONATE; CLINDAMYCIN; CRYSTAL VIOLET; DOXYCYCLINE; ERYTHROMYCIN; EUCALYPTUS OIL; FLAMMACERIUM; FUSIDATE SODIUM; FUSIDIC ACID; HYPOCHLORITE SODIUM; METRONIDAZOLE; NADIFLOXACIN; PLANT EXTRACT; POLYMYXIN B; POVIDONE IODINE; PSEUDOMONIC ACID; RETAPAMULIN; RIFALAZIL; RIFAMPICIN; SILVER; SULFADIAZINE SILVER; TEA TREE OIL; TRICLOSAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WHITE PETROLATUM;

ACNE VULGARIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BURSERA LUNANII; BURSERA SIMARUBA; BURSERACEAE; CONTACT DERMATITIS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; HONEY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SKIN ALLERGY; THRUSH;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 54449084573     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2008.07.004     Document Type: Review

References (63)

1. Desrosiers M., Bendouah Z., and Barbeau J. Effectiveness of topical antibiotics on Staphylococcus aureus biofilm in vitro. Am J Rhinol 21 2 (2007) 149-153
2. Dohmen P.M. Influence of skin flora and preventive measures on surgical site infection during cardiac surgery. Surg Infect (Larchmt) 7 Suppl 1 (2006) S13-S17
3. Smack D.P., Harrington A.C., Dunn C., et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA 276 12 (1996) 972-977
4. Rahimian J., Khan R., and LaScalea K.A. Does nasal colonization or mupirocin treatment affect recurrence of methicillin-resistant Staphylococcus aureus skin and skin structure infections?. Infect Control Hosp Epidemiol 28 12 (2007) 1415-1416
5. Wendt C., Schinke S., Württemberger M., et al. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol 28 9 (2007) 1036-1043
6. Fawley W.N., Parnell P., Hall J., et al. Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. J Hosp Infect 62 3 (2006) 327-332
7. Gould I.M., MacKenzie F.M., MacLennan G., et al. Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an intensive care unit. Int J Antimicrob Agents 29 5 (2007) 536-543
8. Simor A.E., Phillips E., McGeer A., et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 44 2 (2007) 178-185
9. Kniehl E., Becker A., and Forster D.H. Bed, bath and beyond: pitfalls in prompt eradication of methicillin-resistant Staphylococcus aureus carrier status in healthcare workers. J Hosp Infect 59 3 (2005) 180-187
10. Kanazawa K., and Ueda Y. Bactericial activity of chlorhexidine gluconate against recent clinical isolates of various bacterial species in Japan. Jpn J Antibiot 57 5 (2004) 449-464
11. Zhang Y.H., Liu X.Y., Zhu L.L., et al. Study on the resistance of methicillin-resistant staphylococcus aureus to iodophor and chlorhexidine. Zhonghua Liu Xing Bing Xue Za Zhi 25 3 (2004) 248-250
12. Kampf G., Jarosch R., and Ruden H. Limited effectiveness of chlorhexidine based hand disinfectants against methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 38 4 (1998) 297-303
13. Suzuki J., Komatsuzawa H., Kozai K., et al. In vitro susceptibility of Staphylococcus aureus including MRSA to four disinfectants. ASDC J Dent Child 64 4 (1997) 260-263
14. Block C., Robenshtok E., Simhon A., et al. Evaluation of chlorhexidine and povidone iodine activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis using a surface test. J Hosp Infect 46 2 (2000) 147-152
15. Suller M.T., and Russell A.D. Antibiotic and biocide resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. J Hosp Infect 43 4 (1999) 281-291
16. Brenwald N.P., and Fraise A.P. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 55 2 (2003) 141-144
17. Bamber A.I., and Neal T.J. An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J Hosp Infect 41 2 (1999) 107-109
18. Lambert R.J. Comparative analysis of antibiotic and antimicrobial biocide susceptibility data in clinical isolates of methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa between 1989 and 2000. J Appl Microbiol 97 4 (2004) 699-711
19. Noguchi N., Suwa J., Narui K., et al. Susceptibilities to antiseptic agents and distribution of antiseptic-resistance genes qacA/B and smr of methicillin-resistant Staphylococcus aureus isolated in Asia during 1998 and 1999. J Med Microbiol 54 Pt 6 (2005) 557-565
20. Suller M.T., and Russell A.D. Triclosan and antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 46 1 (2000) 11-18
21. Acikel C., Oncul O., Ulkur E., et al. Comparison of silver sulfadiazine 1%, mupirocin 2%, and fusidic acid 2% for topical antibacterial effect in methicillin-resistant staphylococci-infected, full-skin thickness rat burn wounds. J Burn Care Rehabil 24 1 (2003) 37-41
22. Afset J.E., and Maeland J.A. Streptococcus pyogenes to topical antibiotics: indications of clonal spread of fusidic acid-resistant Staphylococcus aureus. Scand J Infect Dis 35 2 (2003) 84-89
23. Mulvey M.R., MacDougall L., Cholin B., Saskatchewan CA-MRSA Study Group, et al. Community-associated methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis 11 6 (2005) 844-850
24. Simor A.E., Stuart T.L., Louie L., et al. Canadian Nosocomial Infection Surveillance Program (CNISP). Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals. Antimicrob Agents Chemother (2007) [Epub ahead of print]
25. Jones J.C., Rogers T.J., Brookmeyer P., et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 45 5 (2007) 541-547
26. Jones R.N., Li Q., Kohut B., et al. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia. Diagn Microbiol Infect Dis 54 1 (2006) 63-71
27. Fung S., O'Grady S., Kennedy C., et al. The utility of polysporin ointment in the eradication of methicillin-resistant Staphylococcus aureus colonization: a pilot study. Infect Control Hosp Epidemiol 21 10 (2000) 653-655
28. Tehrani R. Silver sulphadiazine for MRSA infections. Indian J Dermatol Venereol Leprol 70 3 (2004) 186
29. Schuenck R.P., Dadalti P., Silva M.G., et al. Oxacillin- and mupirocin-resistant Staphylococcus aureus: in vitro activity of silver sulphadiazine and cerium nitrate in hospital strains. J Chemother 16 5 (2004) 453-458
30. Odou M.F., Muller C., Calvet L., et al. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. J Antimicrob Chemother 59 4 (2007) 646-651
31. Rittenhouse S., Biswas S., Broskey J., et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 50 11 (2006) 3882-3885
32. Hurdle J.G., O'Neill A.J., and Chopra I. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J Antimicrob Chemother 54 2 (2004) 549-552
33. Jacobs M.R., and Appelbaum P.C. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother 7 14 (2006) 1957-1966
34. Rothstein D.M., Shalish C., Murphy C.K., et al. Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin Investig Drugs 15 6 (2006) 603-623
35. Shi C.M., Nakao H., Yamazaki M., et al. Mixture of sugar and povidone-iodine stimulates healing of MRSA-infected skin ulcers on db/db mice. Arch Dermatol Res (2007) [Epub ahead of print]
36. Sherry E., Boeck H., and Warnke P.H. Topical application of a new formulation of eucalyptus oil phytochemical clears methicillin-resistant Staphylococcus aureus infection. Am J Infect Control 29 5 (2001) 346
37. Junor G.O., Porter R.B., Facey P.C., et al. Investigation of essential oil extracts from four native Jamaican species of Bursera for antibacterial activity. West Indian Med J 56 1 (2007) 22-25
38. Caelli M., Porteous J., Carson C.F., et al. Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect 46 3 (2000) 236-237
39. Kayama C., Goto Y., Shimoya S., et al. Effects of gentian violet on refractory discharging ears infected with methicillin-resistant Staphylococcus aureus. J Otolaryngol 35 6 (2006) 384-386
40. Okano M., Noguchi S., Tabata K., et al. Topical gentian violet for cutaneous infection and nasal carriage with MRSA. Int J Dermatol 39 12 (2000) 942-944
41. Leaper D.J. Silver dressings: their role in wound management. Int Wound J 3 4 (2006) 282-294
42. Ulkür E., Oncul O., Karagoz H., et al. Comparison of silver-coated dressing (Acticoat), chlorhexidine acetate 0.5% (Bactigrass), and fusidic acid 2% (Fucidin) for topical antibacterial effect in methicillin-resistant Staphylococci-contaminated, full-skin thickness rat burn wounds. Burns 31 7 (2005) 874-877
43. Buxbaum A., Kratzer C., Graninger W., et al. Antimicrobial and toxicological profile of the new biocide Akacid plus. J Antimicrob Chemother 58 1 (2006) 193-197
44. Mosca A., Russo F., and Miragliotta G. In vitro antimicrobial activity of benzalkonium chloride against clinical isolates of Streptococcus agalactiae. J Antimicrob Chemother 57 3 (2006) 566-568
45. Dezzutti C.S., James V.N., Ramos A., et al. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 48 10 (2004) 3834-3844
46. Eady E.A., Gloor M., and Leyden J.J. Propionibacterium acnes resistance: a worldwide problem. Dermatology 206 1 (2003) 54-56
47. Eady E.A., Cove J.H., Holland K.T., et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 121 1 (1989) 51-57
48. Simonart T., and Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 153 2 (2005) 395-403
49. Guay D.R. Topical clindamycin in the management of acne vulgaris. Expert Opin Pharmacother 8 15 (2007) 2625-2664
50. Levy R.M., Huang E.Y., Roling D., et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 139 4 (2003) 467-471
51. Vowels B.R., Feingold D.S., Sloughfy C., et al. Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora. Antimicrob Agents Chemother 40 11 (1996) 2598-2604
52. Mills Jr. O., Thornsberry C., Cardin C.W., et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 82 4 (2002) 260-265
53. Harkaway K.S., McGinley K.J., Foglia A.N., et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 126 6 (1992) 586-590
54. Ross J.I., Snelling A.M., Carnegie E., et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 148 3 (2003) 467-478
55. Cunliffe W.J., Holland K.T., Bojar R., et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 24 7 (2002) 1117-1133
56. Charakida A., Charakida M., and Chu A.C. Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris. Br J Dermatol 157 3 (2007) 569-574
57. Shalita A.R., Smith J.G., Parish L.C., et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 34 6 (1995) 434-437
58. Heller S., Kellenberger L., and Shapiro S. Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic. Antimicrob Agents Chemother 51 6 (2007) 1956-1961
59. Plewig G., Holland K.T., and Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 16 1 (2006) 48-55
60. Fluhr J.W., Bösch B., Gloor M., et al. In-vitro and in-vivo efficacy of zinc acetate against propionibacteria alone and in combination with erythromycin. Zentralbl Bakteriol 289 4 (1999) 445-456
61. Langner A., Sheehan-Dare R., and Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 21 3 (2007) 311-319
62. Dreno B., Foulc P., Reynaud A., et al. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Eur J Dermatol 15 3 (2005) 152-155
63. Weckesser S., Engel K., Simon-Haarhaus B., et al. Screening of plant extracts for antimicrobial activity against bacteria and yeasts with dermatological relevance. Phytomedicine 14 7-8 (2007) 508-516